Welcome to our dedicated page for Integra Lifesciences Hldgs Cp news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra Lifesciences Hldgs Cp stock.
Integra LifeSciences Holdings Corporation reports developments as a global medical technology company focused on neurosurgery and tissue reconstruction. News commonly covers quarterly financial results, revenue guidance, operational execution, supply reliability, quality-management work and product availability across its medical technology portfolio.
Company updates also include clinical evidence and medical-conference activity for wound reconstruction products such as PriMatrix Dermal Scaffold, Integra Dermal Matrices, Cytal Wound Matrix, MicroMatrix and AmnioExcel. Recurring corporate topics include leadership appointments, investor conference presentations, manufacturing progress and segment activity within Codman Specialty Surgical and Tissue Technologies.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) will release its third quarter 2021 financial results on November 2, 2021, before the market opens. A conference call, hosted by management at 8:30 a.m. ET, will discuss the earnings. The call can be accessed at (888) 394-8218 with passcode 7732018, and a webcast will be available on the company’s website. A replay will be accessible until November 12, 2021. Integra specializes in regenerative tissue technologies and neurosurgical solutions, offering a wide range of medical products.
Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leader in medical technology, has announced its participation in two upcoming investor conferences. Carrie Anderson, the executive vice president and CFO, will present at the Wells Fargo 2021 Virtual Healthcare Conference on September 9, 2021, at 11:20 AM ET, and at the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 1:15 PM ET. Interested parties can access the webcasts via the company’s website. Integra specializes in regenerative tissue technologies and neurosurgical solutions.
Integra LifeSciences (IART) reported Q2 2021 revenues of $390 million, a 50.8% increase year-over-year, driven by robust demand in neurosurgery and surgical instruments. GAAP earnings per diluted share rose to $0.41, compared to $(0.00) last year, while adjusted EPS also improved to $0.79. The company raised its full-year revenue guidance by $15 million to between $1,540 million and $1,550 million, and adjusted EPS guidance to $2.98 to $3.05. Cash flow from operations reached $91.3 million, marking a 176% increase.
Integra LifeSciences has announced positive results from a clinical study utilizing its PriMatrix Dermal Repair Scaffold for treating hard-to-heal diabetic foot ulcers (DFUs). Conducted with over 200 patients, the randomized controlled trial found that a single application of PriMatrix, combined with standard care, healed 60% of DFUs within 12 weeks, compared to 35% with standard care alone. This significant improvement highlights PriMatrix's potential for cost-effective treatment, addressing a major health issue affecting millions of diabetics in the U.S.
Integra LifeSciences (Nasdaq: IART) announced that its SurgiMend® Collagen Matrix for soft tissue reconstruction has been awarded an Innovative Technology contract by Vizient, Inc.. This recognition is based on recommendations from healthcare professionals and indicates the product's potential to enhance patient outcomes. SurgiMend is FDA-cleared for surgical repair and demonstrates low recurrence rates in complex abdominal wound reconstruction. The contract reflects SurgiMend's unique qualities that distinguish it from competitors, bolstering Integra's position in the healthcare market.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) will release its second quarter 2021 financial results on July 28, 2021, before market open. The management team will host a conference call at 8:30 a.m. ET, accessible by dialing (800) 367-2403 and using passcode 3706513. A simultaneous webcast will be available on the company’s website. A replay will be accessible until August 7, 2021. Integra is a global leader in regenerative tissue technologies and neurosurgical solutions, providing a comprehensive portfolio of high-quality brands aimed at enhancing patient care.
Peter Arduini will serve as President and CEO of Integra LifeSciences through the end of 2021 before transitioning to a new role at GE Healthcare. The company acknowledges his 11 years of impactful leadership, during which it achieved significant growth and established itself in neurosurgery. A search for a qualified successor has commenced, with expectations to conclude by year-end. Arduini will ensure a seamless transition, maintaining the company's momentum. Integra is well-positioned strategically and financially for ongoing growth.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) hosted an Investor Day, highlighting expectations for Q2 2021 revenues between $372 million and $378 million, and adjusted EPS between $0.63 and $0.67. The company reaffirmed full-year guidance of $1,525 million to $1,535 million in revenue and adjusted EPS of $2.86 to $2.93. Long-term targets include 5% to 7% organic revenue growth and double-digit adjusted EPS growth. The company aims for adjusted gross margins of 70-72% and adjusted EBITDA margins of 28-30% by 2023.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) is set to host an Investor Day meeting on May 20, 2021, from 8:30 a.m. to approximately 12:30 p.m. U.S. Eastern Time. The event will be led by CEO Peter Arduini and the executive leadership team. Interested participants can preregister online and access a live webcast of the presentation on the company’s website. A replay will also be available post-event. Integra is recognized for its innovation in regenerative tissue technologies and neurosurgical solutions.
Integra LifeSciences (NASDAQ: IART) reported Q1 2021 revenues of $360.1 million, a 1.6% increase year-over-year. GAAP earnings per diluted share rose to $0.53 from $0.11 in Q1 2020. The company raised its 2021 revenue guidance by $5 million, targeting between $1,525 million and $1,535 million. Adjusted gross margin was 67.3%, down from 68.3% last year, influenced by revenue shifts and COVID-19 impacts. Adjusted EBITDA increased to $89.9 million, enhancing margins to 25.0%.